Published in Expert Opin Ther Targets on January 01, 2011
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | NCT00895960
Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol (2013) 1.33
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol (2011) 1.11
Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol (2011) 1.06
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs (2012) 1.03
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors. PLoS One (2013) 1.00
Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem (2012) 1.00
Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res (2012) 0.96
Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLoS One (2013) 0.94
The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem (2011) 0.93
Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int (2013) 0.93
Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Clin Pathol (2014) 0.91
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov (2014) 0.88
Filamin C, a dysregulated protein in cancer revealed by label-free quantitative proteomic analyses of human gastric cancer cells. Oncotarget (2015) 0.87
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer (2013) 0.87
Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem (2012) 0.86
The role of EPH receptors in cancer-related epithelial-mesenchymal transition. Chin J Cancer (2013) 0.85
Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem (2014) 0.85
Vaccination strategies for neuro-oncology. Neuro Oncol (2015) 0.85
EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One (2013) 0.85
Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. Br J Pharmacol (2012) 0.85
EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling. J Biol Chem (2015) 0.84
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol (2014) 0.84
Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Mol Cancer (2014) 0.84
High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies. Mol Cell Proteomics (2014) 0.83
Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. ACS Med Chem Lett (2013) 0.83
Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem (2013) 0.83
Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein. Cancer Res (2015) 0.83
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res (2014) 0.82
Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nat Commun (2015) 0.81
The SAM domain inhibits EphA2 interactions in the plasma membrane. Biochim Biophys Acta (2016) 0.80
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem (2013) 0.80
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med (2012) 0.80
Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) (2012) 0.80
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget (2015) 0.78
DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration. PLoS One (2014) 0.78
Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. Electrophoresis (2014) 0.78
Point mutations in dimerization motifs of the transmembrane domain stabilize active or inactive state of the EphA2 receptor tyrosine kinase. J Biol Chem (2014) 0.78
EphA2 Receptor Signaling Mediates Inflammatory Responses in Lipopolysaccharide-Induced Lung Injury. Tuberc Respir Dis (Seoul) (2015) 0.78
A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys Acta (2016) 0.77
Small RNAs deliver a blow to ovarian cancer. Cancer Discov (2013) 0.77
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget (2016) 0.77
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomark Cancer (2016) 0.77
Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One (2014) 0.77
Association between polymorphisms of OGG1, EPHA2 and age-related cataract risk: a meta-analysis. BMC Ophthalmol (2016) 0.76
Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell (2016) 0.75
MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells. Am J Cancer Res (2016) 0.75
High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting. PLoS One (2015) 0.75
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. Int J Mol Sci (2017) 0.75
Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs (2016) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Oncotarget (2017) 0.75
Overexpression and correlation of HIF-2α, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression. Exp Ther Med (2017) 0.75
RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sci (2017) 0.75
Engineering of monobody conjugates for human EphA2-specific optical imaging. PLoS One (2017) 0.75
Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. Biomed Res Int (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A (2003) 12.17
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Signaling--2000 and beyond. Cell (2000) 11.78
Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol (2005) 7.14
Eph-ephrin bidirectional signaling in physiology and disease. Cell (2008) 7.12
Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett (2004) 7.12
Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol (2002) 6.92
Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small (2005) 6.90
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol (2007) 6.56
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Restriction of receptor movement alters cellular response: physical force sensing by EphA2. Science (2010) 3.72
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res (2001) 3.24
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol (2000) 3.09
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Crystal structure of an Eph receptor-ephrin complex. Nature (2002) 2.80
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res (2005) 2.76
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci (2003) 2.17
Molecular plasticity of human melanoma cells. Oncogene (2003) 2.16
Cadherins and catenins in development. Curr Opin Cell Biol (1996) 2.11
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2008) 2.11
Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate (1999) 2.02
EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res (2005) 2.02
E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ (1999) 2.01
cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol (1990) 1.98
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res (2003) 1.98
EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene (2004) 1.95
Nanotechnology: intelligent design to treat complex disease. Pharm Res (2006) 1.95
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Architecture of Eph receptor clusters. Proc Natl Acad Sci U S A (2010) 1.82
Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem (2008) 1.80
The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev (2002) 1.80
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol (2010) 1.80
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res (2001) 1.73
EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol (2002) 1.72
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res (2002) 1.70
EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer (2003) 1.68
Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res (2006) 1.64
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther (2006) 1.57
c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res (2002) 1.57
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 1.57
Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res (2005) 1.57
Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A (1995) 1.56
Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis (2004) 1.55
A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res (2006) 1.54
Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis (2003) 1.53
Protein tyrosine kinases and cancer. Biochim Biophys Acta (1997) 1.52
Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res (2007) 1.52
Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal (2004) 1.51
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther (2004) 1.49
EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (2005) 1.49
Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol (1998) 1.49
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res (2003) 1.48
Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol (2000) 1.47
Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol (2009) 1.46
The Eph family of receptors. Curr Opin Cell Biol (1997) 1.45
EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets (2005) 1.44
Eph-ephrin promiscuity is now crystal clear. Nat Neurosci (2004) 1.44
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
Differential regulation of EphA2 in normal and malignant cells. Am J Pathol (2003) 1.43
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol (2001) 1.42
Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep (2009) 1.42
Ephrins and their receptors: a repulsive topic? Cell Tissue Res (1997) 1.41
Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem (2006) 1.41
VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther (2006) 1.41
Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene (2008) 1.41
EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res (2009) 1.39
Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol (2006) 1.37
B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature (1994) 1.37
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37
MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res (2001) 1.36
Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase. J Biol Chem (1995) 1.36
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res (2009) 1.32
Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer (2010) 1.31
Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene (2001) 1.31
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther (2009) 1.30
Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene (2002) 1.30
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer (2002) 1.30
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res (2005) 1.30
Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J Biol Chem (1994) 1.28
Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer (1999) 1.28
Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci (2004) 1.28
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res (2008) 1.28
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (2006) 2.10
Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther (2008) 1.84
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther (2004) 1.49
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res (2006) 1.24
Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun (2005) 1.19
A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis (2008) 1.13
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res (2004) 1.03
Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology (2002) 1.02
Porcine circovirus type 2 (PCV2) causes apoptosis in experimentally inoculated BALB/c mice. BMC Vet Res (2005) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology (2009) 1.02
Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther (2010) 1.01
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One (2012) 1.00
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther (2005) 0.95
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One (2013) 0.93
Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res (2010) 0.93
Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun (2005) 0.91
Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin. Virology (2005) 0.90
Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology (2009) 0.88
Modulation of PKR activity in cells infected by bovine viral diarrhea virus. Virus Res (2005) 0.86
Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin (2010) 0.85
Sequence analysis of old and new strains of porcine circovirus associated with congenital tremors in pigs and their comparison with strains involved with postweaning multisystemic wasting syndrome. Can J Vet Res (2002) 0.83
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med (2012) 0.80
Adenoviral E2 IVa2 protein interacts with L4 33K protein and E2 DNA-binding protein. J Gen Virol (2013) 0.79
Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res (2011) 0.78
A 72-bp internal deletion in the left inverted terminal repeat of the bovine adenovirus type 3 genome does not affect virus replication. Intervirology (2002) 0.77
Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Res (2013) 0.77
Nanomicroarray and multiplex next-generation sequencing for simultaneous identification and characterization of influenza viruses. Emerg Infect Dis (2015) 0.77
Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines. Virus Res (2011) 0.75
Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res (2013) 0.75
Corrigendum: KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors. Sci Rep (2017) 0.75